Hepatocellular carcinoma (HCC) is the most common malignancy in Taiwan. The prognosis is poor and chemoembolization(TACE) has become the mainstay of treatment for patients with unresectable HCC. However, if tumor progression after TACE, treatment choice is limited. We aims to review various aspects of advanced HCC beyond TACE.